Specialty Pharma Journal Specialty, Precision & Technology
AMSTERDAM–(BUSINESS WIRE)–Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to biosimilar infliximab from originator infliximab.1-10 These studies, presented at the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO), further support the appropriate switching of patients …
Tag Archives: Remsima
March, 2016
June, 2015
-
2 June
Brazil Approves Hospira’s Remsima, a Biosimilar Version of Remicade
The National Health Surveillance Agency in Brazil, ANVISA, has approved the first biosimilars monoclonal antibody for use in the country. Leading biosimilars drugmaker Hospira, Inc. announced that its partner Celltrion has received approval for its Remsima (infliximab) for use in Brazil. The drug is the first biological medication approved by …